2025

Zebrafish models for drug discovery and therapeutic validation against non-tuberculous mycobacteria. M. D. Johansen, C. Hamela, Y. Ding_, and L. Kremer. 2025. Cold Spring Harb. Perspect. Med. 27: a041832.

Remerciements

EccC3 is essential for pathogenesis of rough Mycobacterium abscessus in zebrafish. Y. Tasrini, W. Daher, and L. Kremer. 2025. mSpectrum. In Press.

In vivo antimicrobial activity of engineered mesoporous silica nanoparticles targeting intracellular mycobacteria. J. J. Aguilera-Correa, Y. Tasrini, M. Gisbert-Garzarán, A. Boulay, T. Carvalho, F. P. Blanchet, M. Vallet-Regi, and L. Kremer. 2025. Nat. Comm. 16: 7388.

Deletion of ESX-3 and ESX-4 secretion systems in Mycobacterium abscessus results in highly impaired pathogenicity. W. Daher^*, V. Le Moigne, Y. Tasrini, S. Parmar, D. L. Sexton, J. J. Aguilera-Correa, V. Berdal, E. I. Tocheva, J.-L. Herrmann, and L. Kremer^*. 2025. Commun. Biol. 8: 166. *Corresponding authors.

2024

Trehalose polyphleates participate in Mycobacterium abscessus fitness and pathogenesis.
S. Malmsheimer, W. Daher, Y. Tasrini, C. Hamela, J. J. Aguilera-Correa, C. Chalut, G. F. Hatfull and L. Kremer. 2024. mBio. 30: e0297024. DOI: 10.1128/mbio.02970-24.

High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against non-tuberculous mycobacteria in vitro and in vivo.

P. Ragunathan, P. Sae-Lao, C. Hamela, M. Alcaraz, A. Krah, W. Han Poh, C. Jia Ern Pee, A. Yick Hou Lim, S. A. Rice, K. Pethe, P. John Bond, T. Dick, L. Kremer*, R. W. Bates*, and G. Grüber*. 2024. J. Biol. Chem. 300:105618. *Co-last corresponding authors.

Remerciements

A dTDP-L-Rhamnose 4-epimerase required for glycopeptidolipid biosynthesis in Mycobacterium abscessus.
J. J. Aguilera-Correa, F. Wei, L.-D. Leclercq, Y. Tasrini, E. Mullapudi, W. Daher, K. Nakajima, S. Canaan, J.-L. Herrmann, M. Wilmanns, Y. Guérardel, L. Wen, and L. Kremer. 2024. J. Biol. Chem. 300: 107852. DOI: 10.1016/j.jbc.2024.107852.

2023

In vitro and in vivo efficacy of NITD-916 against Mycobacterium fortuitum.
F. Roquet-Banères*, M. Alcaraz*, C. Hamela*, J. Abendroth, T. E. Edwards, and L. Kremer. 2023. Antimicrob. Agents Chemother. e01607-22. *Co-first authors

2022

Tricyclic SpiroLactams kill mycobacteria in vitro and in vivo by inhibiting type II NADH dehydrogenases.
S. Dam*, S. Tangara*, C. Hamela*, T. Hattabi, L. Faïon, P. Carre, R. Antoine, A. Herledan, F. Leroux, C. Piveteau, M. Eveque, M. Flipo, B. Deprez, L. Kremer, N. Willand, B. Villemagne, and R.C. Hartkoorn. 2022. J. Med. Chem. 65: 16651-16664. *Co-first authors

Glycopeptidolipid glycosylation controls surface properties and pathogenicity in Mycobacterium abscessus.
W. Daher, L.-D. Leclercq, M. D. Johansen, C. Hamela, J. Karam, X. Trivelli, J. Nigou, Y. Guérardel, and L. Kremer. 2022. Cell Chem. Biol. 29: 1-15.

2021

Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline
J. R. Sullivan, A. Lupien, E. Kalthoff, C. Hamela, L. Taylor, K. A. Munro, T. M. Schmeing, L. Kremer, and M. A. Behr. 2021. PLOS Pathog. 17: e1009965.

Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus
D. Johansen, M. Alcaraz, R.M. Dedrick, F. Roquet-Banères, C. Hamela, G. F. Hatfull, and L. Kremer. 2021. Dis. Model. Mech. 14: dmm049159.

2020

Functional Characterization of the N-Acetylmuramyl-l-Alanine Amidase, Ami1, from Mycobacterium abscessus
Küssau T, Van Wyk N, Johansen MD, Alsarraf HMAB, Neyret A, Hamela C, Sørensen KK, Thygesen MB, Beauvineau C, Kremer L, Blaise M.Cells. 2020 Nov 4;9(11):2410. doi: 10.3390/cells9112410.